Table 1. Meta-analyses on in-stent restenosis treatment.
| Author | Date | Patients/trials | Network meta-analysis | Interventions | 1ry end-point | Main result (Better > Worse) | OR (95% CI) |
|---|---|---|---|---|---|---|---|
| Radke et al. (16) | 2003 | 3,012/28 | – | VBT vs. BA | MACE | VBT > BA | −37.7±4.0* |
| Costantini et al. (17) | 2003 | 133 | – | VBT vs. Placebo | BR | VBT > Placebo | 0.06 (0.02-0.17) (+) |
| Uchida et al. (18) | 2006 | 1,310/5 | – | VBT vs. Placebo | MACE | VBT > Placebo | 0.19 (0.09-0.29) |
| Dibra et al. (19) | 2007 | 1,230/4 | – | DES vs. VBT | TLR | DES > VBT | 0.35 (0.25-0.49) |
| Oliver et al. (20) | 2008 | 3,103/14 | – | DES vs. VBT vs. BA | MACE | DES = VBT > BA | 0.72 (0.61-0.85) |
| Alfonso et al. (21) | 2008 | 300/2 | – | DES vs. BMS | BR | DES > BMS | 0.11 (0.03-0.36) (+) |
| Lu et al. (22) | 2011 | 1,942/12 | – | DES vs. VBT | TVR | DES > VBT | 0.44 (0.23-0.81) |
| Yu et al. (23) | 2013 | 349/5 | – | DCB vs. DES/BA | TLR | DCB > DES/BA | 0.17 (0.07-0.38) |
| Navarese et al. (24) | 2013 | 399/4 | – | DCB vs. DES/BA | TLR | DCB > DES/BA | 0.20 (0.11-0.36) |
| Indermuehle et al. (25) | 2013 | 801/5 | – | DCB vs. PES/BA | MACE | DCB > PES/BA | 0.46 (0.31-0.70) |
| Sun et al. (26) | 2014 | 6,330/28 | – | DES vs. Other | TLR | DES > BMS > Other | 0.46 (0.34-0.62) |
| Vyas et al. (27) | 2014 | 1,680/10 | – | SameDES vs. DifDES | TLR | DifDES > SameDES | 0.73 (0.45-0.93) |
| Piccolo et al. (28) | 2014 | 1,586/7 | Yes | DCB vs. DES vs. BA | %DS | DCB = DES > BA | −17.7 (−25- −11)** |
| Mamuti et al. (29) | 2014 | 864/5 | – | DCB vs. DES/BA | MACE | DCB > DES > BA | 0.49 |
| Mamuti et al. (30) | 2015 | 803/4 | – | DCB vs. DES | MACE | DCB = DES | 1.04 |
| Li et al. (31) | 2015 | 1,448/9 | – | DCB vs. DES vs. BA | MACE | DCB = DES > BA | 0.21 (0.13-0.33) |
| Benjo et al. (32) | 2015 | 1,375/5 | – | VBT vs. DES | TLR | DES > VBT | 2.4 (1.5-3.6) |
| Siontis et al. (33) | 2015 | 5,923/27 | Yes | Multiple | %DS | EES > DCB > Other | −9 (−15.8- −2.2)** |
| Lee et al. (6) | 2015 | 2,059/11 | Yes | DCB vs. DES vs. BA | TLR | DCB = DES > BA | 0.22 (0.10-0.42) |
(+), Simple pooled analysis of randomized clinical trials. Other, more than 2 different interventions; *, Probability of MACE (in %); **, %DS, percent diameter stenosis. EES, everolimus eluting stent; DCB, drug coated balloon; VBT, vascular brachytherapy; TLR, target lesion revascularization; DES, drug eluting stent; MACE, mayor adverse cardiac events; DifDES, different (hetero) DES; SameDES, similar (homo) DES; TVR, target vessel revascularization.